Company settles patent infringement lawsuits filed by Novartis regarding SangCya oral solution. In the settlement, SangStat acknowledges that Novartis patents are valid, but still asserts that SangCya does not infringe the patents. The company recalled SangCya July 10 after a study in healthy volunteers demonstrated that SangCya is not bioequivalent to Novartis' Neoral oral solution when mixed with apple juice as recommended in its labeling (1"The Pink Sheet" July 17, p. 13). SangStat said the settlement was unrelated to the recall
You may also be interested in...
SangStat and Abbott are considering launching Abbott's generic cyclosporine oral solution Gengraf following the July 10 recall of SangStat's cyclosporine SangCya, the companies said.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials